Earnings summaries and quarterly performance for ULTRALIFE.
Executive leadership at ULTRALIFE.
Board of directors at ULTRALIFE.
Research analysts who have asked questions during ULTRALIFE earnings calls.
JD
John Deysher
Pinnacle
3 questions for ULBI
Also covers: CODA, CRWS, WEYS
Jake Patterson
TALANTA Investment Group LLC
2 questions for ULBI
Also covers: ACU, HBB
William Lauber
Visionary Wealth Advisors
2 questions for ULBI
Also covers: CSPI
Josh Sullivan
The Benchmark Company, LLC
1 question for ULBI
Also covers: ACHR, CRS, CSTM +8 more
Joshua Sullivan
The Benchmark Company
1 question for ULBI
Also covers: ACHR, AIR, ATI +13 more
JM
Justin Michetti
Sidoti & Company
1 question for ULBI
Recent press releases and 8-K filings for ULBI.
Ultralife Corporation Reports Q3 2025 Results with Increased Sales and Net Loss
ULBI
Earnings
New Projects/Investments
M&A
- Ultralife Corporation reported Q3 2025 sales of $43.4 million, an increase from $35.7 million in Q3 2024, but faced an operating loss of $1 million and a GAAP net loss of $0.07 per share.
- The company's consolidated gross margin declined to 22.2% from 24.3% in the prior year, primarily due to manufacturing inefficiencies from supply chain quality issues and a less favorable sales mix.
- Operating expenses increased to $10.6 million, including $1.1 million in non-recurring costs related to the Electric Chem transition and a $0.5 million provision for the closure of its Calgary facility, which is expected to yield $0.8 million in annual savings in 2026.
- Total backlog increased by 6.5% to $90.1 million exiting Q3 2025, and the company is pursuing new product developments and strategic initiatives, including a company-wide rebranding and the completion of the Electric Chem transition.
Nov 18, 2025, 1:30 PM
Ultralife Corporation Reports Q3 2025 Results with Increased Sales and Net Loss
ULBI
Earnings
New Projects/Investments
M&A
- Ultralife Corporation reported Q3 2025 sales of $43.4 million, an increase from $35.7 million in Q3 2024, but recorded a GAAP net loss of $1.2 million, or $0.07 per share.
- Consolidated gross margin for Q3 2025 was 22.2%, a 210 basis point decline from the prior year, primarily due to manufacturing inefficiencies from supply chain quality issues and sales mix. Operating expenses increased by 29.4% to $10.6 million, including $1.1 million in non-recurring costs related to the Electric Chem transition and the planned closure of the Calgary facility.
- The company's total backlog increased by 6.5% to $90.1 million exiting the third quarter of 2025.
- Strategic actions include the completion of the Electric Chem transition, the closure of the Calgary facility with anticipated annual savings of $0.8 million in 2026, a company-wide rebranding initiative, and continued investment in new product development across both battery and communication segments.
Nov 18, 2025, 1:30 PM
Ultralife Corporation Reports Q3 2025 Sales of $43.4 Million with Net Loss
ULBI
Earnings
M&A
New Projects/Investments
- Ultralife Corporation reported Q3 2025 sales of $43.4 million and a GAAP net loss of $1.2 million, or $0.07 per share.
- The company's consolidated gross margin declined by 210 basis points to 22.2% primarily due to incoming supply chain quality issues and manufacturing inefficiencies, while operating expenses increased by 29.4% to $10.6 million, including $1.1 million in one-time costs.
- Strategic actions include the completion of the Electric Chem transition and the planned closure of the Calgary facility, which is expected to generate annual savings of approximately $0.8 million throughout 2026.
- Total backlog increased by 6.5% to $90.1 million exiting the third quarter, and the company secured a $5.2 million BA53 battery award for delivery throughout 2026.
Nov 18, 2025, 1:30 PM
Ultralife Corporation Reports Q3 2025 Results
ULBI
Earnings
M&A
Layoffs
- Ultralife Corporation reported sales of $43.4 million for the third quarter ended September 30, 2025, marking a 21.5% increase from $35.7 million in the third quarter of 2024, primarily due to the Electrochem acquisition. Excluding Electrochem, sales increased by 2.5%.
- The company recorded a GAAP EPS of ($0.07) and an operating loss of $1.0 million for Q3 2025, compared to GAAP EPS of $0.02 and operating income of $0.5 million in Q3 2024, largely impacted by $1.1 million in one-time non-recurring costs.
- Adjusted EBITDA for Q3 2025 was $2.0 million, a slight increase from $1.9 million in the prior year's third quarter.
- Ultralife's backlog increased to $90.1 million exiting the third quarter of 2025, up from $84.5 million at the end of the second quarter of 2025.
- The company decided to close its Calgary facility, incurring a $0.5 million charge in Q3 2025, and expects to realize annual savings of approximately $0.8 million after the closure is completed in the first quarter of 2026.
Nov 18, 2025, 12:30 PM
Quarterly earnings call transcripts for ULTRALIFE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more